首页 | 官方网站   微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 218 毫秒
1.
目的探讨抑肽酶对二尖瓣置换术患者围体外循环(CPB)期心肌细胞及心肌血管内皮细胞上细胞间粘附分子-1(ICAM-1)、血管细胞粘附分子-1(VCAM-1)表达及心肌细胞凋亡的影响。方法择期二尖瓣置换术患者30例,年龄24~59岁,体重46~73 kg,心功能分级Ⅱ级或Ⅲ级,随机分为2组(n=15):对照组和抑肽酶组,抑肽酶组于CPB转机前,预充液中加入抑肽酶300万KIU,对照组则给予等容量生理盐水,分别于CPB前和CPB停止时取右心房心肌组织标本,采用免疫组织化学SP法染色,检测心肌细胞和心肌血管内皮细胞上ICAM-1、VCAM-1的表达,采用病理图像分析系统对ICAM-1、VCAM-1表达的灰度值作定量分析,采用TUNEL法检测凋亡心肌细胞。结果抑肽酶组CPB停止时ICAM-1、VCAM-1的表达低于对照组(P〈0.01);2组CPB停止时心肌细胞凋亡指数较CPB前增高(P〈0.05),抑肽酶组CPB停止时心肌细胞凋亡指数低于对照组(P〈0.05)。结论预充液中加入抑肽酶300万KIU可抑制二尖瓣置换术患者CPB期间心肌细胞和心肌血管内皮细胞ICAM-1、VCAM-1的表达及心肌细胞的凋亡。  相似文献   

2.
风湿性心脏病心瓣膜置换术围术期细胞黏附分子的表达   总被引:2,自引:0,他引:2  
目的:研究风湿性心脏病心瓣膜置换术围术期细胞黏附分子的表达规律,为临床围术期处理提供依据和参考。方法:采用酶联免疫吸附法(ELISA),分别于体外循环(CPB)前、CPB结束及术后10小时、24小时、3天、6天等6个时点测定35例风湿性心脏病心瓣膜置换术患者外周血清细胞间黏会分子(ICAM-1)、血管细胞黏附分子(VCAM-1)的浓度。结果:ICAM-1和VCAM-1在CPB结束后表达明显增高(P<0.05),并持续维持较高水平。结论:风湿性心脏病患者CPB心瓣膜置换术后ICAM-1、VCAM-1表达上调,参与并介导缺血-再灌注损伤和全身性炎性反应综合征(SIRS),临床上有必要在围术斯进行相应的处理。  相似文献   

3.
目的:研究组织细胞间粘附分子-1(ICAM-1)在阻塞性黄疸(阻黄)小肠粘膜损伤中的作用及丹参防治小肠粘膜损伤机制。方法:SD大鼠48只分为4组:假手术对照组(SO+NS)、阻黄组(BDL+NS)、治疗对照组(SO+SM)及丹参治疗组(BDL+SM),每组术后再随机分设7、14d两个时相点。在不同时相点检测小肠组织髓过氧化物酶活性(MPO)、ICAM-1、二胺氧化酶(DAO)、血浆内毒素水平变化,并与丹参治疗组进行比较。结果:BDL+NS组7、14d时小肠DAO的活性降低,MPO活性增高P<0.05),门表脉血浆内毒素增加,ICAM-1主要表达在小肠粘膜上皮组织,且表达逐渐增强(P<0.05);BDL+SM组7、14d时小肠组织DAO活性显著升高,门静脉血浆内毒素降低,ICAM-1表达受到抑制(P<0.05),MPO改变不明显。结论:阻黄引起小肠上皮细胞上的ICAM-1表达上调,参与了中性粒细胞(PMN)介导的小肠粘膜损伤;丹参是通过抑制ICAM-1的表达而减轻小肠粘膜的损伤。  相似文献   

4.
目的观察心脏跳动中二尖瓣置换术围术期心肌细胞间黏附分子-1(ICAM-1)和血管细胞间黏附分子-1(VCAM-1)的表达。方法30例风湿性二尖瓣病变病人分为两组,试验组(浅低温下阻断主动脉)16例与对照组(中度低温阻断主动脉)14例。分别于CPB前、CPB后30min留取右心房标本,采用免疫组织化学技术检测心肌细胞上ICAM-1和VCAM-1的表达。结果与CPB前比较较,两组CPB后心肌细胞上ICAM-1和VCAM.1的表达明显升高(P〈0.01)。与对照组相比,试验组CPB后ICAM-1和VCAM-1的表达明显降低(P〈0.01)。结论心脏跳动中二尖瓣置换术对心肌细胞上黏附分子的影响较停跳手术少,减轻了术后的炎症反应。  相似文献   

5.
小剂量抑肽酶用于体外循环肺保护的临床研究   总被引:15,自引:0,他引:15  
目的:探讨小剂量抑肽酶对体外循环(CPB)所致急性损伤的保护作用。方法:28例首次择期心脏瓣膜置换术患者随机分为抑肽酶组和对照组,各14例。于麻醉诱导前,CPB前,CPB结束后1h及24h测定TNF-α和IL-10血浆水平,于CPB前,CPB结束后10min,1h测定呼吸指数(RI)。结果:CPB结束后1h及24h,对照组TNF-α明显高于诱导前及相同时点抑肽酶组的水平(P<0.05),CPB结束后1h,两组IL-10均明显增加,但抑肽酶组明显高于对照组(P<0.05);CPB结束后10min及1h,对照组RI较基础值及抑肽酶组明显增高(P<0.05)。结论:小剂量抑肽酶具有抗炎及肺保护作用。  相似文献   

6.
目的:探讨脂多糖(LPS)刺激的人血管内皮细胞(HUVECs)表面ICAM-1 mRNA表达的规律以及高晶体-高胶体渗透压混合液(HHS)对此过程的影响,方法:分离健康产妇脐静脉内皮细胞,进行原代培养,细胞长至单层时用逆转录酶-聚合酶链反应法分析其ICAM-1 mRNA的表达,结果:正常情况下HUVECs表面ICAM-1 mRNA表达微弱,LPS刺激1h后表达开始增加,至4h处达到峰值,0.25%,0.5%高晶体-高胶体渗透压混合液均可明显抑制LPS刺激的ICAM-1 mRNA表达(P<0.05),但两者之间并无明显差异,且其作用时间对ICAM-1 mRNA表达也无明显影响,结论:LPS刺激的ICAM-1 mRNA表达是一个缓慢而持续的过程,HHS可明显抑制脂多糖诱导的ICAM-1 mRNA表达,且这种作用不受HHS浓度及作用时间的影响。  相似文献   

7.
目的 研究胃癌瘤体中血管细胞粘附分子(VCAM-1)对胃癌的血管生成、生长、转移的影响。方法 对30例胃癌、8例胃溃疡,10例正常人标本进行了免疫组化染色、图像分析,分析瘤体VCAM-1的表达与胃癌病理参数的关系。结果 VCAM-1不仅表现在胃癌血管内皮细胞上高表达,在胃癌细胞膜上也有表达,而且VCAM-1的表达强度表达率与胃癌的血管的生成和转移有关。结论 VCAM-1在胃癌的血管生成、瘤细胞转移中可能起到重要作用,其促进了胃癌肿瘤血管的形成。  相似文献   

8.
慢性排斥移植肾中细胞间粘附分子-1与HLA-DR表达的关系   总被引:2,自引:0,他引:2  
目的:探讨慢性排斥移植肾中细胞间粘附分子-1(ICAM-1)和HLA-DR表达与间质淋巴细胞浸润的关系。方法:对20例慢性排斥肾移植受者进行肾活检,采用免疫组化技术(ABC法)检测移植肾内ICAM-1和HLA-DR的表达。结果:ICAM-1在慢性排斥移植肾肾小管上皮细胞和间质微小动脉内皮细胞表达增强,而HLA-DR表达则普遍上调,尤其在远曲小管。此外,在ICAM-1和HLA-DR表达增强的局部血管周围和小管间质伴有大量淋巴细胞浸润。结论:慢性排斥移植肾中ICAM-1和HLA-DR表达增强可能在排斥反应中起诱导作用,尤其是间质炎细胞的浸润及抗原递呈,同时它们又可能使表达上调的细胞成为免疫反应效应支的靶细胞,从而参与慢性排斥的细胞免疫损伤及移植肾间质损害过程。  相似文献   

9.
血小板内皮细胞粘附分子-1在机械通气致肺损伤中的作用   总被引:1,自引:0,他引:1  
目的:探讨血小板内皮细胞粘附分子-1(PECAM-1)在机械通气致肺损伤中的作用。方法:24只普通健康小猪,随机等分为对照组,低潮气量(A组),正常潮气量组(B组)及大潮气量组(C组),持续给予不同潮气量通气,利用免疫组织细胞化学技术,髓过氧化物酶(MPO)测定法及病理组织切片技术,分别检测不同潮气量组通气1d,3d,7d后肺血管内皮细胞表面PECAM-1表达量,血清和肺组织匀浆中MPO活性的变化及肺血管内皮细胞结构及连接的改变。结果:A,B,C组血清,肺组织匀浆MPO活笥较对照组升高(P<0.05或0.01),A,B,C组肺血管内皮组织表面PECAM-1对照组表达下调(P<0.05或0.01),内皮细胞及基膜肿胀,内皮细胞间间隙增大,均以7d后明显,尤以A,C组显著。结论:PECAM-1在机械通气致肺损伤中可能发挥重要作用。  相似文献   

10.
细胞粘附分子在肝细胞癌发生及转移中的作用   总被引:1,自引:0,他引:1  
目的 探讨细胞粘附分子在肝细胞癌发生和转移中的作用。方法 运用cDNA基因芯片和逆转录聚合酶链反应(RT-PCR)技术检测25例肝细胞癌和8例正常肝组织标本中神经细胞粘附分子(NCAM)、细胞内粘附分子(ICAM)、血管细胞粘附分子(VCAM)的表达。结果 基因芯片检测结果提示细胞粘附分子基因在肝细胞癌中表达均显著增高(P<0.05),肝癌转移组与无转移组相差也较明显(P<0.05),RT-PCR检测结果与基因芯片结果相同。结论 基因芯片能够为肝细胞癌的相关基因分析提供特异和可靠的数据。肝细胞癌的发生和转移可能与肝脏组织中粘附分子基因表达升高有关。  相似文献   

11.
目的观察体外循环(CPB)中使用6%羟乙基淀粉130/0.4(6%HES130/0.4)对心脏瓣膜置换术患者细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)及血小板内皮细胞黏附分子-1(PECAM-1)表达的影响。方法选择心脏二尖瓣瓣膜置换术患者60例,ASAⅡ或Ⅲ级,随机分为2组,每组30例。6%HES130/0.4组(Ⅴ组):人工心肺机中预充6%HES130/0.415ml/kg和琥珀酰明胶(Succinyhted Gelatin)对照组(C组):人工心肺机中预充Succinyhted Gelatin 15ml/kg,两组分别于气管插管后至CPB开始前静脉输注6%HES130/0.4和Succinyhted Gehtin 10ml/kg。麻醉诱导后即刻(T0)、CPB主动脉阻断开放时(T1)、CPB结束时(T2)和手术结束时(T3)分别抽取外周动脉血,分离血清。检测血清中游离黏附分子(sAM):sICAM-1、sVCAM-1及sPECAM-1)的含量。结果与C组比较,Ⅴ组T0、T1时血清sICAM-1、sVCAM-1及sPECAM-1的含量差异无统计学意义(P〉0.05);T2、T3时血清sICAM-1、sVCAM-1、sPECAM-1的含量明显减少(P〈0.05)。结论CPB中应用6%HES130/0.4可明显抑制外周血AM的表达,从而减轻CPB触发的炎性反应。  相似文献   

12.
目的 :采用高含量胆固醇建立动脉粥样硬化性阴茎勃起功能障碍 (ED)动物模型并探讨其诱发ED机制。 方法 :30只雄性新西兰大白兔 ,随机分为 2组 :普通饲料 (ND)组 1 0只 ,喂以普通饲料 ;高胆固醇组 2 0只 ,喂以含 1 .5 %胆固醇的饲料。处理 1 2周后观测血脂水平、升主动脉斑块和阴茎勃起情况 ,测定阴部内动脉内膜 /中膜厚度比值 ,以及RT PCR法检测阴部内动脉中血管细胞粘附分子 (VCAM 1 )mRNA表达水平。 结果 :实验过程中共有 5只新西兰大白兔死亡 ,高胆固醇组 3只 ,对照组 2只。喂饲含 1 .5 %胆固醇饲料的新西兰大白兔 1 2周后均出现高脂血症 ,其中 9只发生典型的动脉粥样硬化 (为ATH组 ) ,动脉粥样硬化诱导成功率为 5 2 .9%。ATH组和HCH组 (喂饲高胆固醇但未发生典型动脉粥样硬化者 )TC、TG、AI均显著高于ND组 (P <0 .0 1 )。ATH和HCH组新西兰大白兔阴茎勃起率及阴茎勃起次数均明显降低 ,其中尤以ATH组降低更显著 (P <0 .0 1 )。ATH组阴部内动脉内膜 /中膜厚度比值和VCAM 1mRNA表达水平显著高于HCH和ND组 (P <0 .0 1 )。 结论 :采用高含量胆固醇喂饲新西兰大白兔建立ED动物模型较为简便、可行可靠。高胆固醇血症可能通过VCAM 1损害动脉内皮细胞功能 ,造成动脉内膜增厚、管腔狭窄等所致的阴茎供血不足  相似文献   

13.
Aim: To establish the animal model of atherosclerotic erectile dysfunction (ED) induced by high cholesterol diet and explore the mechanism of atherosclerotic ED. Methods: Thirty male rabbits were divided at random into two groups: the normal diet (ND)group (n=10) and the high cholesterol (HCH) group fed with 1.5% cholesterol diet (n=20). Serum total cholesterol, plaque areas of the ascending aorta,  相似文献   

14.
目的:研究胃癌瘤体中血管细胞粘附分子(VCAM-1)的表达对胃癌的生长,转移的影响及与病理参数之间的关系。方法:对41例胃癌瘤体,瘤旁(2cm)及正常胃组织标本,8例良性胃溃疡,10例正常人标本进行了VCAM-1免疫组化染色,图像分析,分析VCAM-1的表达情况。结果:41例胃癌瘤体中有31例VCAM-1阳性表达,瘤旁组织2cm有5例阳性表达,正常组织5cm有4例阳性表达(P<0.001)。胃良性溃疡8例标本中有2例阳性表达,正常对照10例中有2例阳性表达。胃癌组与溃疡组及正常组VCAM-1的阳性表达差异显(P=0.0006),溃疡组与正常组之间无显性差异(P=0.75)。有淋巴结转移的28例中,VCAM-1阳性表达26例,淋巴结转移阴性的11例中有5例VCAM-1阳性表达(P=0.007)。VCAM-1的表达率及表达强度与胃癌的,分级及浸润深度相关,而与肿瘤的部位,大小无关。结论:VCAM-1表达与胃癌的发生有相关性,VCAM-1可能与胃癌的转移有关。  相似文献   

15.
BACKGROUND: The expression of neutrophil integrin CD11b is up-regulated after cardiopulmonary bypass (CPB) and is the neutrophil adhesive molecule of most importance in neutrophil- endothelial adherence. This neutrophil-endothelial adherence is responsible for post-CPB neutrophil-induced reperfusion injury. Low-dose aprotinin protocols inhibit the CPB-induced neutrophil CD11b up-regulation. This investigation was undertaken to evaluate the effects of pump prime only aprotinin (280 mg) on the CPB-induced up-regulation of this neutrophil integrin. METHODS: Twenty-two patients scheduled for elective myocardial revascularization were randomized into two groups: (1) control (n = 12), or (2) pump prime only aprotinin (280 mg) (n = 10). Neutrophils were isolated at baseline, 50 minutes of CPB, and 30 minutes after CPB and neutrophil CD11b expression was measured. RESULTS: The control group demonstrated a significant (p < 0.05) increase in neutrophil CD11b immunofluorescent staining at 50 minutes of CPB and at 30 minutes after CPB when compared to same group baseline and to the pump prime only aprotinin group at similar time intervals. CONCLUSIONS: These results indicate that pump prime only aprotinin modulates the CPB-induced up-regulation of neutrophil CD11b integrin, an important indicator of the systemic inflammatory response to CPB. In addition to blunting of the CPB-induced up-regulation of this neutrophil integrin expression, this pump prime only dose of aprotinin is also reported to be effective at reducing post-CPB bleeding and transfusion requirements. This salutary effect of pump prime only aprotinin suggests that such low-dose regimens can be both therapeutically effective and cost effective.  相似文献   

16.
BACKGROUND: The administration of aprotinin during cardiopulmonary bypass (CPB) is hypothesized to decrease activation of leukocytes and platelets and possibly reduce their adhesion. Although epsilon-aminocaproic acid (EACA) shares the ability of aprotinin to inhibit excessive plasmin activity after CPB, its effect on leukocyte and platelet activation and leukocyte-platelet (heterotypic) adhesion is largely unknown. This study was performed to determine the relative effectiveness of the antifibrinolytics, aprotinin and EACA, at reducing leukocyte and platelet activation and leukocyte-platelet conjugate formation in patients undergoing CPB. METHODS: Thirty-six patients scheduled to undergo cardiac surgery with CPB were randomized in a double-blind fashion to receive EACA, aprotinin, or saline (placebo). Markers of plasmin activity (D-dimer concentrations), platelet activation (CD62P), leukocyte activation (CD11b), and leukocyte-platelet adhesion (monocyte- and neutrophil-platelet conjugates) were measured before, during, and after CPB. RESULTS: Platelet CD62P (P-selectin), monocyte CD11b, and monocyte-platelet conjugates were all significantly increased (compared with baseline) in the saline group during and after CPB. Despite equivalent reductions in D-dimer formation in patients receiving EACA (P < 0.0001) and aprotinin (P < 0.0001), decreases in platelet CD62P and monocyte CD11b expression were incomplete (not significantly different from saline control). In contrast, peak monocyte-platelet conjugate formation was significantly reduced by both EACA (P = 0.026) and aprotinin (P = 0.039) immediately after CPB. CONCLUSIONS: EACA seems to be as effective as aprotinin at reducing peak monocyte-platelet adhesion after CPB. Furthermore, inhibition of excessive plasmin activity seems to influence monocyte-platelet adhesion. The findings suggest that monocyte-platelet conjugate formation may be a useful marker of monocyte and platelet activation in this clinical setting.  相似文献   

17.
细胞黏附分子与胃癌发生及转移关系的实验研究   总被引:6,自引:1,他引:5  
目的探讨细胞黏附分子在胃癌发生和转移中的作用.方法运用cDNA基因芯片和逆转录聚合酶链反应(RT-PCR)技术检测25例胃癌标本神经细胞黏附分子(NCAM)、细胞间黏附分子(ICAM)、血管细胞黏附分子(VCAM)的表达.结果 NCAM、ICAM及VCAM基因在25例胃癌患者中表达显著增高(Cy5/Cy3>2.0),胃癌转移组明显高于无转移组(P<0.05)和正常对照组(P<0.05),RT-PCR与基因芯片检测结果相同.结论基因芯片能够为胃癌的相关基因分析提供特异和可靠的数据,胃癌的发生和转移可能与胃组织中NCAM、ICAM、VCAM基因表达升高有关.  相似文献   

18.
Background: The administration of aprotinin during cardiopulmonary bypass (CPB) is hypothesized to decrease activation of leukocytes and platelets and possibly reduce their adhesion. Although [epsilon]-aminocaproic acid (EACA) shares the ability of aprotinin to inhibit excessive plasmin activity after CPB, its effect on leukocyte and platelet activation and leukocyte-platelet (heterotypic) adhesion is largely unknown. This study was performed to determine the relative effectiveness of the antifibrinolytics, aprotinin and EACA, at reducing leukocyte and platelet activation and leukocyte-platelet conjugate formation in patients undergoing CPB.

Methods: Thirty-six patients scheduled to undergo cardiac surgery with CPB were randomized in a double-blind fashion to receive EACA, aprotinin, or saline (placebo). Markers of plasmin activity (D-dimer concentrations), platelet activation (CD62P), leukocyte activation (CD11b), and leukocyte-platelet adhesion (monocyte- and neutrophil-platelet conjugates) were measured before, during, and after CPB.

Results: Platelet CD62P (P-selectin), monocyte CD11b, and monocyte-platelet conjugates were all significantly increased (compared with baseline) in the saline group during and after CPB. Despite equivalent reductions in D-dimer formation in patients receiving EACA (P < 0.0001) and aprotinin (P < 0.0001), decreases in platelet CD62P and monocyte CD11b expression were incomplete (not significantly different from saline control). In contrast, peak monocyte-platelet conjugate formation was significantly reduced by both EACA (P = 0.026) and aprotinin (P = 0.039) immediately after CPB.  相似文献   


19.
PDTC对缺氧/再给氧时血管内皮细胞ICAM-1,VCAM-1表达的作用   总被引:3,自引:0,他引:3  
目的为研究心肌缺血-再灌注损伤的机制和治疗途径,检测血管内皮细胞缺氧/再给氧后细胞间黏附分子-1(intracellular adhesion molecule 1,ICAM-1)和血管细胞黏附分子-1(vascular cell adhesion molecule 1,VCAM-1)的表达,探讨抗氧化剂吡咯烷二硫氨基甲酸酯(pyrrolidine dithiocarbamate,PDTC)对血管内皮细胞表面细胞黏附分子表达的抑制作用.方法将培养的人胚肾血管内皮细胞分为3组,缺氧组:细胞经过缺氧/再给氧处理;PDTC组:在缺氧前于培养液中加入PDTC;对照组:未经处理.以多光子激光共聚焦显微镜分别检测3组细胞ICAM-1、VCAM-1的表达情况.结果对照组内皮细胞表面ICAM-1和VCAM-1呈较低表达,缺氧组呈较高表达;PDTC组ICAM-1和VCAM-1的表达明显低于缺氧组,但仍高于对照组.结论缺氧/再给氧促进内皮细胞活化,增强细胞黏附分子的表达,抗氧化剂PDTC能有效降低ICAM-1和VCAM-1的表达,为心肌缺血-再灌注损伤的治疗提供理论基础.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号